Balyasny Asset Management L.P. Has $4.36 Million Stock Holdings in CVRx, Inc. (NASDAQ:CVRX)

Balyasny Asset Management L.P. reduced its holdings in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 32.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 344,165 shares of the company's stock after selling 162,233 shares during the quarter. Balyasny Asset Management L.P. owned approximately 1.42% of CVRx worth $4,361,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of CVRx by 13.9% during the fourth quarter. Bank of America Corp DE now owns 103,207 shares of the company's stock valued at $1,308,000 after buying an additional 12,600 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of CVRx during the fourth quarter valued at approximately $597,000. Emerald Mutual Fund Advisers Trust raised its holdings in shares of CVRx by 28.8% during the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 370,813 shares of the company's stock valued at $4,698,000 after buying an additional 82,978 shares during the last quarter. Northern Trust Corp raised its holdings in shares of CVRx by 4.3% during the fourth quarter. Northern Trust Corp now owns 138,883 shares of the company's stock valued at $1,760,000 after buying an additional 5,671 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its holdings in shares of CVRx by 19.5% during the fourth quarter. Tudor Investment Corp ET AL now owns 75,885 shares of the company's stock valued at $961,000 after buying an additional 12,403 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors.

CVRx Stock Down 2.8%

CVRX traded down $0.15 on Wednesday, reaching $5.29. 614,000 shares of the company traded hands, compared to its average volume of 327,912. The stock's 50 day moving average price is $9.01 and its 200-day moving average price is $12.53. CVRx, Inc. has a 52-week low of $4.30 and a 52-week high of $18.55. The company has a market cap of $137.84 million, a price-to-earnings ratio of -1.97 and a beta of 1.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.03. CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. The firm had revenue of $12.35 million for the quarter, compared to the consensus estimate of $14.68 million. On average, sell-side analysts expect that CVRx, Inc. will post -1.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on CVRX. Lake Street Capital lowered their price objective on shares of CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. William Blair raised shares of CVRx from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 14th. Canaccord Genuity Group lowered their price objective on shares of CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research note on Friday, May 9th. Finally, Craig Hallum lifted their price objective on shares of CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.

Insider Buying and Selling at CVRx

In other CVRx news, Director Kirk G. Nielsen bought 61,200 shares of CVRx stock in a transaction on Wednesday, May 14th. The stock was purchased at an average cost of $5.23 per share, for a total transaction of $320,076.00. Following the completion of the purchase, the director now directly owns 1,899,168 shares of the company's stock, valued at $9,932,648.64. The trade was a 3.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 67,700 shares of company stock worth $351,266 over the last ninety days. 13.90% of the stock is currently owned by insiders.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.